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Abstract
Aims This study aimed to assess plasma fibroblast growth factor 23 (FGF23) in patients with heart failure with preserved
ejection fraction (HFpEF) and its relation to inflammation, renal function, clinical and imaging characteristics, exercise capacity,
and prognosis.
Methods and results We performed a prospective, observational study of 172 age‐matched and sex‐matched subjects
(HFpEF n = 130; controls n = 42, age 73 ± 9, female 50%) who underwent plasma biomarker sampling, echocardiography, car-
diac magnetic resonance imaging, and 6min walk testing (6MWT). The primary endpoint was the composite of all‐cause death
or HF hospitalization. FGF23 was higher in HFpEF compared with controls (62 [42–105] vs. 34 [22–41] pg/mL, P < 0.0001). In
HFpEF, FGF23 correlated with greater symptom burden (New York Heart Association class: r = 0.308), poorer exercise capacity
(6MWT distance: r = 0.345), and plasma biomarkers reflecting inflammation (highly sensitive C‐reactive protein: r = 0.207,
myeloperoxidase: r = 0.311), bone metabolism (osteoprotegerin: r = 0.446), renal dysfunction (urea: r = 0.267, creatinine:
r = 0.351, estimated glomerular filtration rate: r = 0.367), and echocardiographic E/e′ (r = 0.298); P < 0.05. Following mul-
tivariable linear regression modelling, FGF23 remained independently associated with shorter 6MWT distance (P = 0.012) in
addition to age, body mass index, and lower haemoglobin. During follow‐up (median 1428 days), there were 61 composite
events (21 deaths, 40 HF hospitalizations) in patients with HFpEF. In multivariable Cox regression analysis, FGF23 [adjusted
hazard ratio (HR) 1.665; 95% confidence interval (CI) (1.284–2.160; P < 0.0001)], B‐type natriuretic peptide (HR 1.433; CI
1.053–1.951; P = 0.022), and prior HF hospitalization (HR 2.058; CI 1.074–3.942; P = 0.030) were independent predictors of
the composite endpoint.
Conclusions Plasma FGF23 is higher in HFpEF compared with age‐matched and sex‐matched controls and is strongly associ-
ated with exercise incapacity and prognosis. FGF23 correlates with plasma markers of inflammation and renal impairment.
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Introduction
Heart failure (HF) is an increasingly prevalent and important
health care issue. Of incident cases of HF, approximately half
are HF with preserved ejection fraction (EF) (HFpEF), a pro-
portion which has increased over recent years and which is
likely to be the predominant phenotype in the near future.1
While the cause of HF with reduced EF (HFrEF) is usually evi-
dent, and management is based upon a large evidence base,2
the aetiology of HFpEF is often unclear, and there are no spe-
cific evidence‐based treatments.3
HFpEF includes a heterogeneous patient population, which
have in common a typical phenotype, encompassing pre-
served left ventricular (LV) function and abnormal cardiac
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structure in the form of LV hypertrophy (LVH) and atrial dila-
tation, with elevated circulating natriuretic peptides. It is in-
creasingly recognized that a multitude of co‐morbidities,
singly or more often in combination, may contribute to the
development of the HFpEF syndrome3; these include not only
structural myocardial factors but also abnormalities of micro-
vascular and endothelial function possibly driven by inflam-
mation and myocardial energetics.4 Whatever the factors
contributing to the syndrome of HFpEF in the individual pa-
tient, the condition is invariably characterized by exercise
intolerance, the pathophysiological mechanisms of which
are unclear. Fibroblast growth factor (FGF) 23 is a regulator
of bone mineral metabolism circulating in elevated levels in
patients with chronic kidney disease, in whom it is associated
with mortality risk and with progressive renal impairment.5
Circulating FGF23 levels have been associated with risk of
incident cases of HFpEF in community‐based populations6
and of mortality risk in HFrEF.7 Little is known about the role
of FGF23 in HFpEF. In mouse models, FGF23 induces LVH via
activation of the FGF receptor 4 (FGFR4)8,9; the observation
that blockage of FGFR4 attenuates this response10 suggests
a possible direct role for FGF23 in the development of LVH
and thus a possible contribution to the HFpEF phenotype.
The aims of our study were to identify whether FGF23 was
associated with plasma markers of inflammation, renal dys-
function, clinical metrics of disease severity including exercise
capacity, imaging characteristics, and prognosis in patients
with HFpEF undergoing extensive tissue characterization with
cardiac magnetic resonance (CMR).
Methods
Study population
As reported previously,11–13 subjects with a clinical diagnosis
of HFpEF were recruited as part of a prospective, observa-
tional, cohort study conducted in a single, tertiary‐cardiac
centre. The inclusion criteria for HFpEF were as follows: clin-
ical or radiographic evidence of HF, LVEF > 50% on transtho-
racic echocardiography (TTE) and age ≥ 18 years. Exclusion
criteria were as follows: documented myocardial infarction
(MI) in the preceding 6 months, suspected or confirmed car-
diomyopathy [e.g. hypertrophic cardiomyopathy (HCM) amy-
loid] or constrictive pericarditis, severe native valve disease,
non‐cardiovascular life expectancy < 6 months, severe pul-
monary disease (forced expiratory volume < 30% predicted
or forced vital capacity < 50% predicted), estimated glomer-
ular filtration rate (eGFR) < 30 mL/min/m2, and standard
contraindications to CMR imaging.
HFpEF patients were compared with asymptomatic
age‐matched and sex‐matched controls without known car-
diac disease. The control population did include individuals
with a history of hypertension (50%), because this is highly
prevalent in the general population as well as in HFpEF, and
the aim for our study was to identify factors differentiating
between patients with and without HFpEF.
During a single study visit, all subjects underwent clinical
assessment of New York Heart Association (NYHA) status,
blood sampling, TTE, CMR, standardized 6 min walking test
(6MWT),14 and Minnesota Living with Heart Failure (MLHF)
questionnaire15 evaluation. The study conformed with the
principles outlined in the Declaration of Helsinki. The research
protocol was approved by the UK National Research Ethics
Service (reference: 12/EM/0222). Written informed consent
was obtained from all subjects prior to participation. The
study was registered on Clinicaltrials.gov (NCT03050593).
Plasma sampling and analysis
At recruitment, blood sampling was undertaken for B‐type
natriuretic peptide (BNP; immunoassay, Siemens, Erlangen,
Germany), haematocrit, haemoglobin, and renal function
and assayed in our hospital laboratory.
Blinded single batch testing of FGF23, osteoprotegerin
(OPG), highly sensitive C‐reactive protein (hs‐CRP), and
myeloperoxidase (MPO) was undertaken from residual super-
natant plasma stored at 80°C in cryotubes using a Luminex®
bead‐based multiplex assay,16 enabling high‐throughput bio-
marker profiling as previously described.17
Transthoracic echocardiography
Echocardiography (iE 33 System, Philips Medical Systems,
Best, the Netherlands) was performed as previously
detailed.11–13 For study inclusion, LVEF was calculated using
the biplane method or visually estimated in subjects with
poor endocardial border definition. Trans‐mitral Doppler
was used to measure the early diastolic inflow E wave. Tissue
Doppler measured medial and lateral mitral annular tissue ve-
locities (e′) were averaged to derive E/e′ as an overall mea-
sure of diastolic dysfunction.
Cardiac magnetic resonance
The CMR protocol used has previously been detailed.11–13 All
scans were performed on a 3 Tesla platform (Siemens Skyra,
Erlangen, Germany). In brief, the protocol comprised the fol-
lowing: standard breath‐held steady‐state free precession
long‐axis and short‐axis cine imaging; short‐axis pre‐contrast
and post‐contrast T1 maps; and late gadolinium enhance-
ment (LGE) imaging. The total contrast dose administered
was 0.15 mmol/kg of Gadovist (Bayer Healthcare, Berlin,
Germany).
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All CMR analyses were performed by a single observer
(P. K.) blinded to clinical data, using CVI42 software (Circle
Cardiovascular Imaging, Calgary, Canada). LV volumes, EF,
and mass (excluding papillary muscles) were calculated from
the short‐axis cine stack.11,12 Left atrial (LA) volumes and EF
(LAEF) were derived from the biplane method, excluding
the appendage and pulmonary veins.11 All volumetric and
mass data were indexed to body surface area (BSA). LGE
was assessed qualitatively for the presence and pattern of fo-
cal fibrosis and categorized as MI or non‐MI fibrosis, requiring
consensus by two experienced observers (P. K. and G. P. M.).
Extracellular volume (ECV) and ECV indexed to BSA (iECV)
were also calculated as measures of diffuse myocardial fibro-
sis from mid‐ventricular T1 maps, as reported recently by our
group with excellent reproducibility.12
Follow‐up and endpoints
The primary endpoint was a composite of all‐cause mortality
or hospitalization for HF (defined as a hospital admission for
which HF was the primary reason and necessitating diuretic,
inotropic, or intravenous nitrate therapy). Only first events
were included in the outcome analysis. All subjects
underwent a minimum of 1 year follow‐up, post‐study entry.
Outcome data were sourced from hospital records.
Statistical analysis
SPSS V25 (SPSS Inc., Chicago, Illinois) was used for statistical
testing. Summary data are presented as mean ± standard de-
viation or median [25–75% inter‐quartile range (IQR) or
range]. Between group differences were compared using
the t‐test, Mann–Whitney U‐test, and the χ2 test, as appro-
priate. BNP, creatinine, eGFR, and all plasma biomarkers were
log10 transformed before analysis. 6MWT distance was
square root transformed.
Spearman’s correlations were performed to check for po-
tential associations of FGF23 with continuous variables in
HFpEF patients. Multivariable linear regression modelling
was undertaken to determine variables independently associ-
ated with 6MWT distance. P < 0.05 was considered
significant.
Event rates were calculated from Kaplan–Meier analysis.
Differences in survival curves were tested using the log‐rank
test. To account for missing data (iECV in a small minority
as reported previously12), imputation was undertaken five
times, and results were averaged in agreement with Rubin’s
rules during survival analysis. Cox proportional hazards analy-
sis was initially undertaken to identify baseline variables asso-
ciated with the composite endpoint. Individual covariates
associated with the endpoint at P < 0.1 were then entered
into multivariable analysis to identify independent predictors
using both backwards and forwards stepwise elimination
methods. Four separate, clinically relevant multivariable
models were generated including a final model incorporating
the strongest predictors. Generally, multivariable models
were limited to no more than six parameters, allowing for ap-
proximately one parameter/10 composite events. The final
model however was also adjusted for additional,
well‐recognized prognosticators [e.g. blood pressure (BP)
and NYHA class] and potential confounders (renal function
and inflammatory biomarkers), independent of their P values.
Continuous variables were Z‐standardized to enable compar-
ison of hazard ratios (HRs) based upon one standard devia-
tion increase in the predictor variable. Receiver operator
characteristic (ROC) analysis was undertaken to gauge the ac-
curacy of the final independent Cox model to predict adverse
events.
Results
The overall study recruitment is shown in Figure 1. Following
CMR, 15 patients with HFpEF were newly diagnosed with
HCM or constrictive pericarditis and excluded from further
analysis.13 Of the remaining 188 study subjects who
underwent CMR, 16 had missing FGF23 data (HFpEF n = 10,
controls n = 6). The final cohort with complete plasma bio-
marker profiles comprised 130 HFpEF patients and 42 con-
trols. As reported previously, ECV and iECV could not be
calculated in a small subset of consecutive HFpEF (n = 42,
32%) and controls (n = 3, 7%) owing to unavailability of the
T1 mapping sequence at the time of the CMR scan.12
Heart failure with preserved ejection fraction
compared with controls
Baseline clinical and imaging characteristics are shown in
Tables 1 and 2 respectively. Both HFpEF and controls exhib-
ited similar age (73 years) and gender split (male 50%). HFpEF
was characterized by a high prevalence of obesity, hyperten-
sion, diabetes, and atrial fibrillation. NYHA class III/IV
symptoms (31%), angina (17%), and lung disease (15%) were
noted in significant minorities of HFpEF.
Compared with controls, HFpEF was characterized by
markedly lower exercise capacity [6MWT distance (median
180 m vs. 380 m; P < 0.0001)], lower haemoglobin, worse re-
nal function, increased LV mass, and more concentric LV
remodelling (mass/volume). Surrogate markers of diastolic
dysfunction, that is, echocardiographic E/e′, BNP, maximal
left atrial volume index [LAVImax], and LAEF were worse in
HFpEF. Focal (MI and non‐MI) and diffuse (ECV and iECV)
fibrosis were greater in HFpEF. Plasma biomarkers associated
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with inflammation (hs‐CRP, MPO) and OPG were also higher
in HFpEF (Table 1).
Plasma fibroblast growth factor 23 in heart
failure with preserved ejection fraction
FGF23 levels were significantly higher in HFpEF compared
with controls [62 (42–105) vs. 34 (22–41) pg/mL,
P < 0.0001] and irrespective of whether controls were hyper-
tensive or normotensive (P < 0.0001 for each). FGF23 levels
did not differ significantly between hypertensive and
non‐hypertensive controls (P = 0.920).
HFpEF baseline characteristics stratified according to me-
dian FGF23 (62 pg/mL) are also shown in Tables 1 and 2.
HFpEF patients with FGF23 above the median plasma concen-
tration experienced lower systolic BP, more frequent prior HF
hospitalization, more prevalent AF, greater prescription of
loop diuretics, worse renal function (urea, creatinine, and
eGFR), worse exercise capacity (greater proportion of NYHA
III/IV and reduced 6MWT distance), higher LV filling pressures
(E/e′), and lower LAEF. MLHF scores were worse in the higher
FGF23 group, albeit statistical significance was not reached
(P = 0.080). HFpEF patients with above‐median FGF23
showed higher levels of plasma hs‐CRP, MPO, and OPG.
There were no significant differences in CMR measured LV
or LA volumes and function or LV mass and fibrosis according
to median FGF23 in HFpEF.
The results of FGF23 correlation analyses in HFpEF are
shown in Table 3. Moderate strength correlations were
noted with clinical parameters. Higher FGF23 correlated with
the following: lower systolic and diastolic BP, more advanced
NYHA class, lower haemoglobin and E/e′, lower 6MWT dis-
tance, poorer renal function, and higher plasma levels of
hs‐CRP, MPO, and OPG. No significant associations were
noted between FGF23 and any CMR parameter with the ex-
ception of a weak correlation (β  0.194, P = 0.030) with LV
end‐diastolic volume indexed to BSA (LVEDVI). Specifically,
FGF23 did not correlate with CMR measures of established
association with prognosis: ECV (r = 0.116, P = 0.280), iECV
(r = 0.031, P = 0.778), LAVImax (r = 0.023, P = 0.795),
LAVImin (r = 0.093, P = 0.293), and LAEF (r = 0.166,
P = 0.058).
FGF23 levels increased with worsening NYHA status (Figure
2). The results of univariable and multivariable linear regres-
sion modelling for 6MWT distance are shown in Table 4. Cre-
atinine, eGFR, LVEDVI, and indexed LV end‐systolic volume
(LVESVI) exhibited collinearity. Overall, FGF23 (β  0.198,
Figure 1 Study overview. Consort diagram illustrating recruitment, reasons for exclusion, and missing data. CMR, cardiovascular magnetic resonance
imaging; HFpEF, heart failure with preserved ejection fraction.
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P = 0.012), age (β  0.343, P = 0.0001), body mass index
(BMI) (β  0.397, P = 0.0001), and haemoglobin (β 0.213,
P = 0.006) were independently associated with 6MWT dis-
tance. The final multivariable model yielded the following
values; R = 0.592, R2 = 0.351, adjusted R2 = 0.328. The R2
and adjusted R2 values for the contribution of FGF23 towards
the final model were 0.121 and 0.114, respectively. The rela-
tionship between FGF23 and 6MWT distance is illustrated in
Figure S1.
Survival analysis
During median follow‐up of 1428 days (IQR 1153–1663),
there were 61 first clinical events (21 deaths and 40 HF hos-
pitalizations) in patients with HFpEF. No events were ob-
served in the control group.
Cox regression analysis
Sixteen variables showed univariate association with adverse
outcomes (Table 5). Clinical variables were as follows: greater
age, prior HF hospitalization, NYHA III/IV symptoms, lower di-
astolic BP, and 6MWT distance. Laboratory indices associated
with increased risk of end points were as follows: lower
haemoglobin and eGFR, and higher levels of creatinine,
BNP, and FGF23. Imaging parameters included higher E/e′,
LV mass indexed to BSA (LVMI), LAVImax, ECV and iECV,
and lower LAEF. Of these, eGFR and ECV were excluded from
multivariable analysis due to co‐linearity. On multivariable
analysis (Table S1), FGF23 remained associated with outcome
in three separate models incorporating clinical factors, blood










n = 65 P value
Echocardiography
E/e’ 13 ± 5 9 ± 3 <0.0001 12 ± 5 14 ± 5 0.016
CMR
LV
LVEF (%) 56 ± 5 58 ± 5 0.048 57 ± 5 55 ± 5 0.294
LVEDV (mL) 160 ± 41 145 ± 33 0.033 166 ± 40 156 ± 44 0.163
LVEDVI (mL/m2) 79 ± 18 80 ± 14 0.565 82 ± 18 76 ± 19 0.054
LVESV (mL) 71 ± 23 62 ± 18 0.016 73 ± 23 70 ± 24 0.455
LVESVI (mL/m2) 35 ± 10 34 ± 8 0.511 36 ± 11 34 ± 10 0.265
LVM (g) 108 ± 33 81 ± 21 0.0001 109 ± 37 108 ± 31 0.842
LVMI (g/m2) 52 ± 15 45 ± 9 <0.0001 53 ± 16 52 ± 14 0.465
LV mass/LV volume 0.68 ± 0.16 0.57 ± 0.09 <0.0001 0.66 ± 0.15 0.69 ± 0.17 0.228
LA
LAVmax (mL) 106 ± 47 61 ± 22 <0.0001 104 ± 47 111 ± 48 0.357
LAVImax (mL/m2) 53 ± 25 34 ± 12 <0.0001 52 ± 24 55 ± 27 0.410
LAVmin (mL) 77 ± 48 30 ± 13 <0.0001 71 ± 48 85 ± 50 0.101
LAVImin (mL/m2) 38 ± 26 17 ± 7 <0.0001 35 ± 24 42 ± 27 0.126
LAEF (%) 32 ± 16 51 ± 10 <0.0001 36 ± 16 28 ± 15 0.004
Tissue characterization
ECV (%) 28 ± 5 25 ± 3 <0.0001 27 ± 4 28 ± 5 0.418
iECV 14 ± 4 11 ± 2 <0.0001 13 ± 4 14 ± 5 0.329
LGE positive – MI (%) 20 (15) 0 (0) 0.004 7 (11) 13 (20) 0.145
LGE positive – non‐MI (%) 47 (36) 5 (12) 0.001 24 (37) 23 (35) 0.855
Abbreviations as per Table 1.
ECV, extracellular volume; EDVI, end‐diastolic volume indexed; EF, ejection fraction; ESVI, end‐systolic volume indexed; iECV, indexed ECV;
LAVImax, maximal left atrial volume indexed; LGE, late gadolinium enhancement; LV, left ventricle; LVMI, left ventricular mass indexed.





Systolic BP 0.255 0.004








Lg creatinine 0.351 <0.0001
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Figure 2 Association of fibroblast growth factor 23 with New York Heart Association status.
Table 4 Univariable and multivariable linear regression models for the associations with 6 min walking test
Univariable analysis Multivariable analysis
Standardized coefficients (β) P value Standardized coefficients (β) P value
Clinical
Age 0.294 0.001 0.343 0.0001
Gender (male) 0.197 0.029
Diastolic BP 0.225 0.012
BMI 0.323 0.0001 0.397 0.0001
Blood
Lg creatininea 0.189 0.037
Lg eGFRa 0.298 0.001
Haemoglobin 0.253 0.005 0.213 0.006
Lg BNP 0.181 0.045





Model R = 0.592, R2 = 0.351, adjusted R2 = 0.328.
aVariables that exhibited significant co‐linearity; of these, Lg eGFR and LVEDVI were entered into multivariable analysis.
Table 5 Univariable predictors for the composite endpoint of death and/or hospitalization with heart failure
Univariable predictors of outcome
Hazard ratio (95% CI) P value
Clinical
Age 1.346 (1.047–1.730) 0.020
Prior HF hospitalization 2.745 (1.456–5.175) 0.002
Diastolic BP 0.645 (0.483–0.861) 0.003
NYHA 3/4 1.649 (0.983–2.763) 0.058
Square root transformed 6MWT 0.720 (0.536–0.969) 0.030
Clinical blood samples
Haemoglobin 0.733 (0.570–0.941) 0.015
Lg creatinine 1.328 (1.045–1.689) 0.020
Lg eGFRa 0.821 (0.660–1.020) 0.075
Lg BNP 1.565 (1.132–2.164) 0.007
Lg FGF23 1.732 (1.356–2.211) <0.0001
Imaging
E/e′ 1.504 (1.180–1.918) 0.001
LVMI 1.305 (1.002–1.699) 0.048
LAVImax 1.266 (1.012–1.582) 0.039
LAEF 0.762 (0.590–0.984) 0.037
ECVa 1.612 (1.136–2.287) 0.008
iECV 1.732 (1.151–2.606) 0.008
aParameters not entered into Cox regression multivariable modelling due to co‐linearity.
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sampling, and imaging parameters. In a final model compris-
ing the strongest predictors overall as well as diastolic BP,
NYHA class, Lg creatinine, Lg hs‐CRP, and Lg MPO, FGF23 [ad-
justed HR 1.665; 95% confidence interval (CI) 1.284–2.160;
P < 0.0001] remained an independent predictor along with
Lg BNP (HR 1.433, CI 1.053–1.951; P = 0.022) and prior HF
hospitalization (HR 2.058; CI 1.074–3.942; P = 0.030). Plots
of the scaled Schoenfeld residuals against time were centred
around zero with no time‐dependent trend, suggesting that
the proportional hazards assumption was upheld using the
functional forms supplied to the Cox models. The final inde-
pendent Cox model to predict outcomes yielded and area un-
der the ROC curve of 0.786 (P < 0.0001).
Kaplan–Meier analysis
Kaplan–Meier survival curves stratified according to median
FGF23 are shown in Figure S2. Above‐median FGF23 levels
in HFpEF were associated with markedly elevated risk of ad-
verse outcome (HR 3.171, CI 1.544–6.510, log‐rank
P < 0.0001).
Discussion
In this extensively phenotyped cohort of patients with HFpEF,
higher FGF23 was associated with more severe HF, as evi-
denced by higher NYHA class and BNP, lower systolic and di-
astolic BP, and higher LV filling pressure (E/e′). Furthermore,
higher FGF23 was associated with evidence of more ad-
vanced anaemia and renal dysfunction, as well as with evi-
dence of systemic inflammation. Importantly, we observed
independent associations between higher circulating FGF23
concentrations and exercise capacity (6MWT), and the risk
of death or hospitalization with HF in patients with HFpEF.
FGF23 is a regulator of bone mineral, vitamin D, and iron
homeostasis; in turn, FGF23 production is regulated by vari-
ous factors including iron deficiency and inflammation.18 Ele-
vated FGF23 levels are seen in chronic kidney disease, where
they are associated with adverse outcome5 and in cohorts
with stable ischaemic heart disease19 and HFrEF.20 There
are very few prior reports relating to FGF23 in HFpEF. In
the TIME CHF study, FGF23 was found to be higher in HFpEF
than in HFrEF but was not associated with risk of death or HF
hospitalization.21 Similarly, FGF23 was not associated with
mortality risk in patients undergoing coronary angiography
in the Ludwigshafen Risk and Cardiovascular (LURIC) Health
Study.22 While our observations of increased risk of adverse
outcome in association with elevated FGF23 appear to con-
trast with those of TIME CHF and LURIC,21,22 the former in-
cluded only 73 patients with HFpEF, and neither was a
specific study of HFpEF. Our observed association between
circulating FGF23 and risk of death or HF hospitalization in
HFpEF confirms similar findings from a retrospective analysis
of the Treatment of Preserved Cardiac Function Heart Failure
with an Aldosterone Antagonist (TOPCAT) Trial23 as well as
from a recently published prospective, observational study.24
Furthermore, our outcome data benefit from substantially
longer follow‐up: median 44 vs. 34 and 30 months.
The rationale for the link between FGF23 and adverse
outcomes in HFpEF is not clear. It is known that FGF23 is as-
sociated with prognosis in, and progression of, chronic
jkidney disease5 and with risk of incident HF in
community‐based populations6 and in patients with HFrEF.7
A direct causative link between FGF23 and adverse out-
comes is supported by the established link between FGF23
and LV remodelling in clinical studies25,26 and the induction
of LVH by FGF23 in animal models,8,9 an effect attenuated
by blockade of the FGFR4 receptor.10 While it may be postu-
lated that FGF23 is associated with prognostic risk via its as-
sociation with renal impairment,5 our data indicate that FGF
provides information over and above knowledge of renal
function, as indicated by the independent association of
both FGF23 and parameters of renal function in multivariate
association with outcomes.
Our observation of association between circulating FGF23
and adverse outcome in HFpEF is in keeping with that from
a recent study24 of similar sample size as our cohort. Similar
to our study, these authors found FGF23 to be higher in
HFpEF compared with controls and to be associated with
plasma NT‐proBNP levels and more prevalent atrial fibrilla-
tion. Moreover, as in the present report, the previous study
found FGF23 levels to be associated with risk of all‐cause
death or HF hospitalization. While our study did not find asso-
ciation with ECV in contrast to the previous report,24 we sug-
gest there are consistent observations in the two studies,
with differences in the characteristics of the populations, in
imaging techniques, and in parameters considered in multi-
variate analyses, all likely to contribute to variation in the
strength of observed associations.
Importantly, to the association with adverse prognosis,
we report an additional association for FGF23 with reduced
exercise capacity in HFpEF. HFpEF is a syndrome character-
ized by limitation of exercise capacity, in the presence of
preserved LVEF, LVH, and elevated plasma natriuretic pep-
tides. Our cohort of 130 patients demonstrated the arche-
typal HFpEF phenotype, with LVEF comparable with the
matched control cohort (56 vs. 58%), moderate elevation
of BNP, and clearly elevated LV mass and filling pressures.
Exercise capacity in patients with HFpEF was reduced mark-
edly, with median 6MWT distance (180 m) less than half of
that compared with age‐matched and sex‐matched controls
(vs. 380 m).
A number of clinical variables demonstrated univariate as-
sociation with 6MWT distance, including parameters of renal
impairment (eGFR and creatinine) and plasma FGF23 (Table
3). In this context, the independent association with lower
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6MWT distance of greater age, lower haemoglobin, higher
BMI, and higher FGF23, but not of eGFR or creatinine, is of
note. As with the association with prognosis, we cannot as-
cribe a causal relationship between elevated FGF23 and re-
duced 6MWT distance. However, potential contributors to
this apparent effect include the potential for FGF23 to induce
LVH, and its association with progressive renal impairment, as
already noted. However, using gold standard CMR imaging,
we failed to observe any correlation between indices of
FGF23 with LV mass indices. Alternatively, FGF23 may pro-
mote myocardial fibrosis and remodelling via activation of
the renin–angiotensin–aldosterone system27 and may con-
tribute to the development of anaemia28; we did observe a
relatively strong inverse association between FGF23 and
haemoglobin and treatment of iron deficiency in HF is known
to result in reduction in FGF23 levels.29 Whether blockade of
FGF23 would result in improvement in parameters of
haemoglobin and indeed of LVH in HFpEF is not known.
With regard to exercise capacity in HFpEF, we note the lack
of multivariate association with 6MWT distance for any imag-
ing parameter. While elevated filling pressure (E/e′) and mea-
sures of LV remodelling (LVEDVI and LVESVI) showed
univariate associations, these were not retained after adjust-
ment for covariates. As well as higher age and BMI and lower
haemoglobin, higher FGF23 was the only laboratory parame-
ter to retain a multivariate association with poorer exercise
capacity. We suggest that this observation supports a possi-
ble direct link between FGF23 and exercise capacity in this pa-
tient group.
FGF23 plays a pivotal role in bone mineral homeostasis,
and levels increase in response to increasing phosphate levels
and increase as renal impairment progresses. In this context,
we noted elevated circulating levels of a second biomarker
related to mineral metabolism and OPG in our patients with
HFpEF, with a relatively strong correlation between FGF23
and OPG levels (r = 0.446, P < 0.0001). Clustering of these
peptides as markers of outcome in HFpEF has been reported
in one previous study,23 the relevance of elevated markers
of bone mineral metabolism in HFpEF merits further
investigation.
Potential implications of our study
Our data indicate that FGF23 appears to be associated with a
more severe clinical phenotype of HFpEF, conferring addi-
tional prognostic information beyond standard clinical char-
acteristics and enables patients to be stratified into high‐risk
and low‐risk groups. Furthermore, FGF23 appears intimately
involved in pathways of inflammation, serving as a potential
therapeutic target and also as a biomarker of treatment
response.
Limitations
Our study has a number of strengths and weaknesses. Our
patients with HFpEF were phenotyped in detail with CMR im-
aging complementing transthoracic echo and detailed bio-
marker assessment. Importantly, our patients underwent
standardized 6MWT assessment of exercise capacity. To-
gether, our observations of association of FGF23, and the lack
of association of CMR imaging parameters, with exercise ca-
pacity can be regarded as relatively robust. However, we ac-
knowledge that these associations should be assessed in
additional populations of patients with HFpEF. The overall
study sample size is relatively small, and the limited number
of events is also a limitation. While FGF23 levels were only
measured at baseline in our cohort, repeat plasma sampling
over time may offer improved precision for the estimation
of risk. The single‐centre nature of our study is a clear poten-
tial weakness. Furthermore, we do not have serum phos-
phate or iron levels. While we observed associations
between FGF23 and a number of clinical parameters, and
with well‐defined end points, we are not able to ascribe a
cause‐and‐effect relationship with risk of death or HF hospi-
talization. However, we have outlined possible pathways by
which FGF23 may be directly related to these events, and in-
deed to reduce exercise capacity in HFpEF, which merit fur-
ther investigation in future clinical studies in the
increasingly prevalent HFpEF population.
Conclusions
In conclusion, FGF23 levels are elevated in patients with
HFpEF compared with age‐matched and sex‐matched control
subjects and are associated with reduced exercise capacity
and increased risk of death or HF. Future studies of possible
mechanistic links between FGF23 and prognosis in HFpEF
are merited.
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Figure S1. Association of fibroblast growth factor 23 with six
minute walk test distance.
Caption: Scatter plot illustrating the relationship between Log
fibroblast growth factor 23 with square root transformed six
minute walk test distance.
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